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ABSTRACT
Despite many clinical advances in allogeneic hematopoietic cell transplantation (HCT), the one factor that
is consistently required to apply HCT to a wide variety of diseases is the successful donation and the safe
transport and administration of viable donor cells to the HCT recipient. Since 1987, the National Marrow
Donor Program (NMDP) has maintained a registry of volunteer HCT donors for those patients who lack
a suitable related donor, facilitated the donor search, and managed the collection and transportation of do-
nor cells to transplant centers for use in increasingly complex therapies. The NMDP has collected data on
marrow and peripheral blood stem cell (PBSC) donations as well as additional donations of lymphocytes,
whole blood, or platelets. These additional donations are provided for a variety of reasons, including treat-
ing post-transplant complications such as graft failure or relapsed disease, supporting immune reconstitu-
tion or providing transfusion support. For donor safety, rates of placement of central venous catheters for
collecting PBSC are monitored. Data have also been collected on rare events that may affect the integrity
of the HCT product (e.g., graft clotting or leaks from the transport bag). Quality assurance and review of
these donation processes is an essential component of the transplantation approach. Data from the broad
NMDP experience further illuminate factors surrounding the donation process and product integrity.
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Allogeneic hematopoietic cell transplantation
(HCT) has become a widely applied therapy for both
hematologic and non-hematologic, malignant and
non-malignant diseases. Since 1987, the National
Marrow Donor Program (NMDP) has facilitated the
identification, donation, and delivery of cells from
a suitably matched, unrelated donor to patients who
lack an appropriate related donor.Withmore sophisti-
cated transplantation approaches, supportive care, andprocedures for HLA-matching, the use of cells from
NMDP donors has been applied to an increasingly
diverse and growing population of patients. The provi-
sion of the HCT graft by the donor is an essential
component of the HCT, yet few large databases are
available to describe the experiences of an individual
donor and the characteristics of the HCT product.
We describe the activities of NMDP donors, in-
cluding those involving multiple marrow or peripheral
blood stem cell (PBSC) donations as well as the23
24 C. D. Bolan et al.donation of additional blood products for immune
reconstitution, transfusion support, or treatment of
post-transplant complications. Also described are the
events that may have an impact on the integrity of
the HCT product such as bag breakage or visual
clumping or clotting of the product.
METHODS
Study Population and Time Frame
This report summarizes the donation activities of
bone marrow donors from 1987 through 2007, and
of PBSC donors from 1994 through 2007. Donation
activity and CD341 cell counts/PBSC yields were ob-
tained from standard reports for each donation. Since
1987, the NMDP has required that all transplant cen-
ters perform microbial culture testing on each HCT
graft.
RESULTS
Donor Activity
Single donations. The majority of NMDP donors
donated a single HCT product for one recipient. A to-
tal of 25,336 unique donors made 26,878 donations
from 1987 through 2007. Of these 25,336 donors,
23,859 (94%) made a single HCT donation. An addi-
tional 1477 donors donated more than one HCT
product, either for the same recipient or for more
than one recipient.
Multiple donations. Between 1987 and 2007, of
the 25,336 NMDP donors who have donated, 870
(3.4%) donated more than one HCT product to a sin-
gle recipient, including 857 who donated 2 times and
13 who donated 3 times (Table 1). Among those do-
nors who donated twice for the same recipient, the ma-
jority initially donated bone marrow and then PBSC
(51%), whereas approximately equal numbers of do-
nors provided bone marrow (23%) or PBSC (22%)
for both the first and second HCT donation. Only
Table 1.Donations by Cell Source from Donors Providing Multiple HCT
Grafts to a Single Recipient
1st Donation 2nd Donation 3rd Donation N %
Bone marrow PBSC 446 51%
Bone marrow Bone marrow 196 23%
PBSC PBSC 189 22%
PBSC Bone marrow 26 3%
Bone marrow Bone marrow PBSC 5 1%
Bone marrow Bone marrow Bone marrow 3 \1%
Bone marrow PBSC PBSC 3 \1%
Bone marrow PBSC Bone marrow 1 \1%
PBSC Bone marrow PBSC 1 \1%
870 100%
HCT indicates hematopoietic cell transplantation; PBSC, periph-
eral blood stem cell.3% of donors initially donated PBSC followed later
by bone marrow.
In contrast, 626 (2.5%) donors provided an HCT
product to more than one recipient; 602 donated
HCT for 2 different recipients, 23 donated HCT to
3 different recipients, whereas one donated bone mar-
row to 4 different HCT recipients (Table 2). Among
the 602 recipients who donated for 2 different recipi-
ents, the majority of donors donated bone marrow
for both recipients (53%). Less commonly, donors do-
nated bonemarrow for the first recipient and PBSC for
the second recipient (27%), or PBSC for 2 recipients
(12%). Only 4% of multiple donations consisted of
PBSC for the first recipient and then bone marrow
for the second recipient.
Of the 1300 subsequent (second, third, fourth)
HCT, 1241 (95%) were second HCT, 57 were third
HCT, and 2 were fourth HCT (Table 3). As shown
in Figure 1, whereas the absolute number of subse-
quent transplants has increased over time, since 1994
the percentage of subsequent HCT has remained be-
tween 3% and 6% of all transplants. Second trans-
plants were performed for graft failure or delayed
engraftment (46%) and relapse (34%), compared
with graft failure (47%) and relapse (25%) for those
undergoing a third transplant (Table 3).
Donors also provided additional blood products to
support the transplant and later complications (Table
4). Unstimulated leukocytes for use in supporting im-
mune reconstitution or treating relapse or graft failure
were collected most frequently (82%). Whole blood
and blood tubes were the next most frequently col-
lected product. Platelets were donated only rarely,
and no platelet collections have been documented
since 2002.
Product collected but not infused. Although
rare, there were occasionally times when a donated
product was not infused in the recipient. This was al-
most always because of the declining physical condi-
tion of the recipient. Of the 16,641 donations for
a first NMDP bone marrow transplant from 1987
through 2007, there were 59 (0.4%) donated products
that were not infused. Of the 9068 donations for a first
NMDP PBSC transplant from 1997 through 2007,
there were 47 (0.5%) donated products that were not
infused. For the same time periods, the percentages
of bone marrow and PBSC products collected but
not infused were 1.2% (5 of 406) and 1.6% (14 of
855) for subsequent (second, third, or fourth) bone
marrow and PBSC transplants, respectively.
Filgrastim injections administered but product
not collected. Of the 9995 donors who received fil-
grastim injections from 1994 through 2007, 72
(0.7%) received at least 1 injection of filgrastim but
did not have PBSC collected. The cancelled collec-
tions were almost always because of the declining
physical condition of the recipient.
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1st Recipient 2nd Recipient 3rd Recipient 4th Recipient N %
Bone marrow Bone marrow 330 53%
Bone marrow PBSC 171 27%
PBSC PBSC 73 12%
PBSC Bone marrow 28 4%
Bone marrow Bone marrow PBSC 11 2%
Bone marrow Bone marrow Bone marrow 9 1%
Bone marrow PBSC PBSC 2 \1%
Bone marrow PBSC Bone marrow 1 \1%
Bone marrow Bone marrow Bone marrow Bone marrow 1 \1%
626 100%
HCT indicates hematopoietic cell transplantation; PBSC, peripheral blood stem cell.Central line placement. The NMDP protocol
for collection of PBSC allows for central venous lines
to be placed in the donor if blood flow from the stan-
dard peripheral venous line is not adequate. The site of
central line placement in male and female donors is de-
tailed in Figure 2, whereas the frequency of line place-
ment over time in male and female donors is shown in
Figure 3. For donors undergoing a 1-day collection,
the frequency of internal jugular and femoral line
placement was similar, with both the internal jugular
and femoral locations utilized twice as often as the sub-
clavian vein. In contrast, the femoral location was uti-
lized much less frequently for donors scheduled to
undergo a 2-day collection. Since the year 2000, the
frequency of line placement has remained relatively
stable at approximately 2% to 5% in male donors
and 18% to 24% in female donors. Over the time pe-
riod of data collection, the proportion of collections
with central lines was significantly greater for 1-day
(624 of 4477 collections, 14%) versus 2-day collec-
tions (201 of 3387 collections, 6%, P\ .001).
Peripheral blood CD341 cell mobilization and
PBSC yields. Figure 4 shows the day 5 peripheral
blood CD341 cell count following filgrastim adminis-
tration but prior to PBSC collection. For all donors,
filgrastim was administered at a targeted dose of 10
to 12 mg/kg of body weight subcutaneously for 5 con-
secutive days. As shown in Figure 5, the actual PBSC
yield following apheresis was highly correlated withthe peripheral blood CD341 cell count, indicating
the high predictive impact of this parameter on the
overall CD341 cell content of the graft. For both
men and women, the post-filgrastim CD341 cell
counts prior to apheresis increased with increasing
donor weight, and thus with increased total filgrastim
administered. CD341 cell counts were similar in men
and women who weighed between 80 and 120 kg,
whereas women at lower body weights had somewhat
lower CD341 cell counts than men at lower body
weights.
Data in Figure 5 were used to calculate the effi-
ciency of PBSC collection by apheresis, (CD341 cells
in the apheresis product per liter of whole blood pro-
cessed divided by the CD341 cell concentration in
the peripheral blood). For the nearly 3000 collections,
the mean collection efficiency was 38% (95% confi-
dence interval 37-38). Ten of 101 (10%) collection
centers (mean of 28 collections per center) had mean
collection efficiency values with an upper 95% confi-
dence limit that was 10% or more below this overall
mean value (i.e., less than a mean efficiency of 34%).
Product Integrity
Positive product culture results in PBSC grafts.
A positive product microbiologic culture was reported
in 29 PBSC grafts. Other than infusion reactions,
no long-term effects of bacteremia and no deaths at-
tributable to sepsis were reported. In 5 instances theTable 3. Reasons for Undergoing Second, Third, and Fourth Transplants
2nd Transplant 3rd Transplant 4th Transplant
Reason N Percent N Percent N Percent
Graft issues 567 46% 27 47% 2 100%
Relapse 424 34% 14 25% 0
Product issues 11 1% 0 0
2nd malignancy 8 1% 1 2% 0
Planned 2nd transplant 1 \1% 0 0
Other 15 1% 1 2% 0
Unknown 215 17% 14 25% 0
1241 100% 57 100% 2 100%
26 C. D. Bolan et al.recipient developed fever, chills, nausea, hypotension,
or other complications consistent with infection; in 1
instance hemolysis from incompatible plasma may
have contributed to the clinical event. In 19 of the 29
events, the positive culture was reported by the apher-
esis center. Of these 19 events, 18 were confirmed neg-
ative by testing at the transplant center, and 1 was not
tested at the transplant center. In the remaining 10
events, the transplant center reported a positive result
with testing either not done or results not available at
the apheresis center. In 21 of the 29 events where data
on antibiotic therapy was available, 10 recipients were
already receiving prophylactic antibiotic therapy, 9 re-
ceived antibiotic therapy upon receipt of the bacterio-
logic report, and 2 were not started on antibiotic
therapy as testing at the transplant center was negative.
Of the 28 recipients for whom engraftment data was
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Figure 1. Number of subsequent (second, third, fourth) NMDP-
facilitated transplants, by transplant year.
Table 4. Additional Blood Products Collected for NMDP Transplant
Recipients
Year of
Transplant
Unstimulated
Leukocytes
Whole
Blood Blood Tubes Platelets
1993 1 8 0 0
1994 23 5 4 0
1995 16 10 1 0
1996 36 17 5 0
1997 40 10 12 0
1998 53 11 6 0
1999 54 11 10 0
2000 56 13 19 1
2001 86 3 15 0
2002 84 6 5 1
2003 113 7 6 0
2004 132 12 13 0
2005 133 5 14 0
2006 154 5 8 0
2007 162 2 14 0
1143 125 132 2
82% 9% 9% \1%
From 1993 to 2007, there were 1402 additional blood products
collected from 1316 donors to support a total of 1315 recipients.available, engraftment was reported in 26 of the 28 re-
cipients who received a possibly contaminated prod-
uct. Organisms identified included Staphyloccocus
species (13), propionobacteria, diptheroids, and
gram-variable rods (5), gram-positive cocci (4), Salmo-
nella (2), Bacillus species (2), fungus (2), Pseudomonas
species (1), Gram negative (1), and others (4).
Positive culture reports in bone marrow prod-
ucts. Positive cultures were reported in 145 bone
marrow products. Of these 145 events, 69 were re-
ported positive by the transplant center. Of the re-
maining 76 events reported positive by the collection
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Figure 2. Placement of central lines according to anatomic location
for donors undergoing 1-day and 2-day PBSC collections in male
and female donors. For donors scheduled for a 1-day collection,
the frequency of central line placement was similar in the internal
jugular and femoral locations, each of which occurred more than
twice as frequently as placement in subclavian or other locations.
In contrast, the frequency of femoral line placement was less com-
mon, whereas the frequency of internal jugular and subclavian vein
placement was more common in donors scheduled to undergo
a 2-day collection.
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Figure 3. Frequency of male and female donors receiving central
venous catheter placement, by year of collection. The rate of line
placement has remained stable since the year 2000 for both male
and female donors, at between 18% and 24% for females, and be-
tween 2% and 5% for males.
Donor Activity and Product Integrity 27center, 68 were confirmed negative by the transplant
center and 8 were not tested at the transplant center.
No deaths were attributed to infusion of these prod-
ucts. In 13 recipients, unexpected symptoms including
fever, hypotension, hypertension, nausea, changes in
heart rate, or hypoxia were reported. In 78 cases the re-
cipient was already receiving prophylactic antibiotic
therapy at the time of the positive culture report; 38 re-
cipients were placed on antibiotic therapy following
the positive culture report. Of the 129 recipients for
whom engraftment status was known, engraftment
was reported in 118. A total of 172 positive culture re-
ports identified Staphylococcus species in 57 products,
propionobacteria, diptheroids, corynebacteria, and
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Figure 4. Peripheral blood CD341 cell counts in female and male
donors following administration of filgrastim subcutaneously for 5
days at a targeted dose of 10 to 12 mg/kg/day. In both female and
male donors, the CD341 cell count increased with increasing donor
weight (higher total amounts of filgrastim). Higher responses were
also observed in male compared to female donors with body weights
of\80 kg.
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Figure 5. Apheresis PBSC collection efficiency, plotted as the
CD341 cell yield per liter, processed versus the CD341 cell concen-
tration in peripheral blood at the beginning of apheresis. The prod-
uct yield was highly correlated with the pre-apheresis CD341 cell
count. The collection efficiency was 38%, indicating that the prod-
uct yield increased by 0.38 106/L processed for every 1 106 cell/L
increase in the pre-apheresis CD341 concentration.gram-positive or gram-variable rods in 47 products,
gram-positive cocci in 37 products, peptostreptococ-
cus in 6 products, Micrococcus species in 7 products,
fungus or mold species in 8 products, Clostridia species
in 2 products, and 8 others.
Product clotting. Product clotting was reported in
only 5 PBSC and 5 marrow products. For the 5 PBSC
products, no unexpected adverse events were reported.
One of the PBSC products was filtered, 3 had addi-
tional anti-coagulant added, 1 had no specific interven-
tion made, and 1 was infused via syringe with visual
inspection. A median infused cell dose of 6  106
CD341 cells/kg recipient weight was reported and en-
graftment occurred in 4 of 4 recipients with available
data. In the 5 bone marrow products, 1 adverse event
was noted when a recipient complained of dyspnea 1
hour after infusion, with resolution 1 hour later.
Two of the bone marrow products were filtered, 2
were filtered and had additional anti-coagulant added,
1 had no additional interventionmade. Themedian in-
fused nucleated cell dose was 1.2  108/kg and only 1
of 3 products with available data engrafted.
Compromised product bags. Three PBSC prod-
ucts had bag leaks and breakage reported upon receipt
by the transplant center. Culture results were negative
in all 3 cases. One was infused using prophylactic anti-
biotics, 1 was transferred to another bag, and 1 case
had no specific intervention. Engraftment occurred
in all 3 recipients. Four bone marrow products were
reported to have bag leaks and breakage; 3 were re-
ported by the transplant center, and 1 by the collection
center. Culture results were negative in all 4 cases.
Two were infused after transfer to another product
bag, and 2 had no specific intervention. Engraftment
occurred in all 4 cases.
Nonstandard product transport. NMDP
standards for product transport indicate that the prod-
uct must be maintained within a specified temperature
range and must not be subject to airport x-ray exami-
nation. During this period, 10 PBSC products were
identified as having undergone incorrect transport;
4 were x-rayed during transport and 6 arrived at incor-
rect temperature. All 10 products were infused without
specific intervention and engraftment was reported in
all 10. Four bone marrow products were identified
by the transplant center as having undergone incorrect
transport; 1 was x-rayed and 3 arrived at incorrect tem-
perature. All 4 were infused without specific interven-
tion; engraftment was reported in 2 of 2 recipients with
available data.
SUMMARY
The data reported herein indicate that NMDP
network transplant recipients may receive a second
or more unrelated HCT graft primarily as a therapy
for relapsed disease or graft failure, and that altruis-
tic, volunteer donors may at times provide a second,
28 C. D. Bolan et al.third, or, very rarely, a fourth donation of HCT cells
to the same or to a different recipient. Also, donors
not infrequently provide additional blood products
to promote improved recipient outcomes. The
majority of these products are unstimulated mono-
nuclear cell apheresis products for immunotherapy
of graft failure or relapse.
The donation process for PBSC involves adminis-
tration of filgrastim to increase circulating levels of
CD341 cells in blood, and may require placement of
indwelling central venous catheters. The collection
of PBSC also involves expertise in assessing the choice
of peripheral venous access versus central line place-
ment, and operation of sophisticated apheresis devices
for collection of the donor PBSC graft. The degree of
mobilization of the donor CD341 cells and the effi-
ciency of CD341 cell collection may substantially af-
fect the quantity of cells in the PBSC graft. This may
be an important consideration for engraftment, espe-
cially in larger weight recipients and in transplant
approaches utilizing complex cell processing therapies.
Absent widely and readily available data for perfor-
mance standards and outcome data regarding this
process, this information may be used to track and
improve these elements that have an impact on both
donors and recipients.
Product integrity may rarely be compromised, pri-
marily by positive microbial product cultures, but alsoby rarer events involving apparent clotting of the prod-
uct, breaks, or leaks in the product bags. Errors can
occur during the transport process. Although system-
atic procedures to follow-up on all these events were
incomplete, in general, these uncommon product
integrity compromise events had little impact on the
recipients’ outcome. Only in a few cases of clotted
marrow products was there an association with graft
failure, but the rarity of the cases reinforces confidence
that the network procedures, when followed, provide
a safe and satisfactory graft product for almost every
recipient.
Through additional internal review, analysis, and
dissemination of corrective procedures within the
NMDP network of centers, examination of these
events may improve science, understanding, and pro-
cesses to enhance the donor and recipient safety as
transplantation of hematopoietic products continues
to expand.
ACKNOWLEDGEMENTS
Financial Disclosure: Drs. J. Miller, R. Miller,
Hanley, Chitphakdithai, and King are employees of
the NMDP and have a financial relationship with the
NMDP, in that capacity as employees. Drs. Bolan,
Hartzman, Perry, and Trainor have nothing to dis-
close.
